GSK account plan
Science-led global healthcare
At a glance
GSK is a biopharma group selling specialty medicines, vaccines and general medicines, with 2025 turnover of £32.7bn and 66,800 people.
GSK describes itself as a focused biopharma company that discovers, develops and delivers specialty medicines, vaccines and general medicines, with R&D centred on respiratory, immunology and inflammation, oncology, HIV (through ViiV Healthcare) and infectious diseases. It employs 66,800 people across 70 countries and runs 33 manufacturing sites. 2025 turnover was £32.7bn (+7% CER) and Core operating profit £9.8bn (+11% CER, margin 29.9%), with Core EPS of 172.0p and free cash flow of £4.0bn. The US is its largest region at £16.9bn of 2025 sales.
Business units
Specialty Medicines
41% of 2025 turnover (£13.5bn)Medicines for complex or rare chronic conditions: HIV (£7.7bn, led by Dovato and long-acting Cabenuva and Apretude through ViiV Healthcare, run by Deborah Waterhouse), RI&I (£3.8bn, Nucala, Benlysta and the new Exdensur) and Oncology (£2.0bn, +43%, Jemperli, Ojjaara, Blenrep). Sales grew 17% CER in 2025, and GSK expects the unit to exceed 50% of sales by 2031.
Vaccines
28% of 2025 turnover (£9.2bn)Shingrix (£3.6bn, a record year with ex-US at 66% of its sales), meningitis vaccines led by Bexsero, Arexvy for RSV and established vaccines. Sales grew 2% CER in 2025 as US demand for Shingrix and Arexvy declined, then rose 8% to £2,284m in Q2 2026.
General Medicines
31% of 2025 turnover (£10.0bn)Primary-care medicines supplied in more than 100 countries, mostly respiratory and infectious disease; Trelegy (£3.0bn) offsets generic erosion. Sales fell 1% CER in 2025 and 9% in Q2 2026 as US Medicare changes hit Trelegy; spend is being reallocated to launches.
Strategic priorities
- More than £40bn of sales by 2031
- GSK targets sales above £40bn by 2031, with 15 launch opportunities each with peak sales potential above £2bn, and Specialty Medicines above 50% of sales.
- Maximising launches
- The CEO's 2026 focus starts with launch products such as Exdensur (twice-yearly severe asthma treatment) and Blenrep (multiple myeloma).
- Accelerating the late-stage pipeline
- A review accelerated 7 late-stage products across 18 indications, and GSK now expects 20+ phase III starts in 2026 (previously 10), including oncology ADCs, efimosfermin in MASH and long-acting TSLP.
- Longer-acting HIV medicines
- ViiV targets three-times-yearly Apretude for PrEP in H1 2027, three-times-yearly Cabenuva in 2028 and twice-yearly treatment by the end of the decade, to navigate the dolutegravir loss of exclusivity.
- Targeted business development
- Deals with a clear pathway to value creation: RAPT Therapeutics, 35Pharma and Nuvalent in 2026, after 14 partnerships and acquisitions in 2025.
- Technology and AI at scale
- The Chair asks the new CEO to adopt technology at scale; technology and AI are one of three R&D priorities and a source of savings in the Accelerate Growth programme.
Latest results
In Q2 2026, sales were £8,409m (+5% CER) and H1 sales £16,038m (+5% CER). Core operating profit rose 7% to £2,800m with a 33.3% margin, and Core EPS rose 9% to 50.5p. Specialty Medicines grew 14% to £3,782m and Vaccines 8%, while General Medicines fell 9%. Total operating profit fell 75% to £481m on a £1,334m camlipixant impairment and £371m on Alector-related assets. Guidance for 2026 at CER was reaffirmed: turnover +3% to 5% and Core operating profit +7% to 9%, both in the upper half, and Core EPS +7% to 9% in the lower half.
Investments and deals
- Nuvalent acquisition
- Closed 15 July 2026 for an equity value of about $10.6bn, funded mainly by debt, adding zidesamtinib and neladalkib in lung cancer.
- RAPT Therapeutics and 35Pharma
- RAPT (US$2.3bn, completed 3 March 2026) adds ozureprubart for food allergy; 35Pharma (US$1.0bn, completed 14 April 2026) adds HS235 for pulmonary hypertension.
- Accelerate Growth programme
- Targets £1.9bn of annual savings by 2029 for £2.4bn of costs, through technology and AI, support services, procurement and a simpler supply chain and site network; savings are mainly reinvested in R&D and business development.
- Manufacturing and R&D sites
- $1.2bn over five years in US advanced manufacturing, AI and digital, including a biologics flex factory at Upper Merion, Pennsylvania; a new flagship R&D centre is planned on the Cambridge Biomedical Campus, UK.
Challenges and risks
- US pricing and policy
- US policy on international reference pricing, tariffs and the IRA Medicare Part D redesign weigh on sales; the April 2026 agreement gives Section 232 tariff relief through 20 January 2029.
- Dolutegravir loss of exclusivity
- Dolutegravir loses exclusivity during 2028-2030, starting April 2028 in the US, with most of the impact in 2029-2030.
- Weaker US vaccine demand
- US demand for Shingrix and Arexvy declined in 2025, with Shingrix US sales down 17%, amid vaccine hesitancy and competition.
- Pipeline setbacks
- The CALM-1 and CALM-2 trials of camlipixant showed limited efficacy, leading to a £1,334m impairment in Q2 2026.
- Cyber and supply continuity
- The annual report rates information and cyber security and supply continuity among principal risks increasing externally.
What leadership says
“Accelerating R&D is our biggest opportunity to create value as a company.”
“Products are the key in this business, and we need to be more product-centric.”
“We remain focused on operational delivery, execution, and accelerating R&D.”
“has underperformed for many years and this marks only the start of a long-awaited recovery.”
Where a supplier can help
- Clinical trial capacity
- Tied to the pipeline acceleration: going from 10 to 20+ phase III starts in 2026 creates demand for CROs, site networks and trial technology.
- Launch commercialisation support
- Tied to the Exdensur and Blenrep launches: patient access, field-force and HCP engagement services for launches GSK calls its first focus area.
- AI, procurement and support-service efficiency
- Tied to the Accelerate Growth programme: savings are to come from technology and AI, streamlining support services and procurement.
- Manufacturing and site network
- Tied to the US manufacturing investment and supply-chain simplification: equipment, automation and digital tools for new and consolidated sites.
- Integration of acquired biotechs
- Tied to the Nuvalent, RAPT and 35Pharma acquisitions: systems, data and regulatory integration of newly acquired programmes.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like GSK?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- GSK Annual Report 2025
- GSK is a focused biopharma group (66,800 people, 70 countries, 33 manufacturing sites) selling Specialty Medicines, Vaccines and General Medicines, with R&D centred on RI&I, oncology, HIV (via ViiV Healthcare) and infectious diseases.
- 2025 turnover £32.7bn (+7% CER); Core operating profit £9.8bn (+11% CER, margin 29.9%); Core EPS 172.0p (+12%); free cash flow £4.0bn; dividend 66p.
- Specialty Medicines is the growth engine: £13.5bn (41% of sales, +17% CER), with HIV £7.7bn, RI&I £3.8bn and Oncology £2.0bn (+43%); expected to exceed 50% of sales by 2031.
- Vaccines £9.2bn (+2% CER): Shingrix £3.6bn record year, ex-US now 66% of its sales; US demand for Shingrix and Arexvy declined. General Medicines £10.0bn (-1% CER), Trelegy £3.0bn offsetting generic erosion.
- Five major FDA approvals in 2025 (Exdensur, Blenrep, Nucala in COPD, Blujepa, Penmenvy); 58 pipeline assets, 15 launch opportunities by 2031 each with peak sales potential above £2bn.
- Targets: sales above £40bn by 2031; 2026 guidance of turnover +3-5%, Core operating profit and Core EPS +7-9% at CER; 2026 dividend expected at 70p.
- Leadership change: Luke Miels replaced Emma Walmsley as CEO at end-2025 and expanded the team into a new Executive Committee with US, Europe and International presidents and a Global Product Strategy head.
- Investing in US manufacturing ($1.2bn over five years) and AI, and in targeted business development (IDRx, efimosfermin, Hengrui, RAPT Therapeutics).
- Key risks: US drug pricing (December 2025 agreement with the US Administration, tariffs), IRA Medicare Part D, dolutegravir loss of exclusivity in 2028-2030, cyber and supply continuity.
- GSK Second quarter 2026 results announcement
- Q2 2026 sales £8.4bn (+5% CER); H1 sales £16,038m (+5% CER). Core operating profit £2.8bn (+7%), Core EPS 50.5p (+9%); Core operating margin 33.3%.
- Total operating profit fell 75% to £481m on a £1.3bn camlipixant impairment after the CALM-1/2 phase III trials, plus £371m on Alector-related assets and higher CCL charges.
- Specialty Medicines £3.8bn (+14%): HIV £2.1bn (+10%), RI&I £1.1bn (+19%), Oncology £0.6bn (+17%). Vaccines £2.3bn (+8%) with Arexvy and meningitis up; General Medicines £2.3bn (-9%), Trelegy -7% on US Medicare changes.
- New "Accelerate Growth" programme: £1.9bn annual savings by 2029 for £2.4bn of costs, savings mainly reinvested in R&D and business development; 7 late-stage assets accelerated across 18 indications; 20+ phase III starts expected in 2026 (previously 10).
- Acquired Nuvalent for about $10.6bn (closed 15 July 2026), adding zidesamtinib/Jideytro (FDA approved) and neladalkib in lung cancer; also RAPT ($2.3bn) and 35Pharma ($1.0bn) closed in H1.
- 2026 guidance reaffirmed: turnover +3-5% and Core operating profit +7-9% (both upper half), Core EPS +7-9% (lower half); 2031 sales outlook of more than £40bn reaffirmed.
- New flagship R&D centre planned on the Cambridge Biomedical Campus, UK. Q2 dividend 17p; £2bn buyback completed; net debt £15.1bn at 30 June 2026.
- US: definitive agreement of 9 April 2026 gives Section 232 tariff relief through 20 January 2029; GSK and ViiV joined the CMS Generous Model.
- FY & Q4 2025 results: conference call and webcast transcript
- Luke Miels' first results call as CEO (4 February 2026): 2025 sales up 7% to more than £32bn, Specialty Medicines up 17%, Core operating profit +11%, EPS +12%, dividend raised 2p to 66p.
- Three 2026 focus areas: maximise launches (Blenrep, Exdensur), accelerate late-stage assets (B7-H3, B7-H4, velzatinib, efimosfermin, long-acting TSLP, six-monthly HIV regimen), and business development such as the RAPT/ozureprubart deal.
- Two value levers: topline (2031 ambition and the dolutegravir loss of exclusivity) and pipeline; GSK must be "more product-centric" with "more scientific courage".
- Commercial reshuffle: all Nucala reps moved to Exdensur; Nucala COPD promoted by the Trelegy team; Nucala has 43% to 46% of new COPD patient starts.
- HIV (Deborah Waterhouse): +11% in 2025, over 75% of growth from long-acting injectables; CUATRO four-monthly treatment to file in 2027 and launch in 2028; six-monthly treatment launch targeted 2028-2030.
- 2026 guidance (Julie Brown): sales +3-5%, Core operating profit and EPS +7-9%, dividend 70p; cash generated from operations on track for more than £10bn in 2026; profit growth weighted to H2.
- Miels on resources: GSK will "rapidly move resources, people, head count, capital" to the best opportunities, and reiterated the £40bn 2031 sales commitment.
- Q1 2026 results: conference call and webcast transcript
- Q1 2026 call (29 April 2026): sales up 5% to more than £7.6bn, Specialty Medicines +14%, Core operating profit +10%, EPS +9%; Q1 dividend 17p; 2026 guidance confirmed.
- Shingrix set a quarterly record above £1bn (+20%), with Europe +51%; Jemperli £232m (+40%); Nucala has around 45% of the US COPD market share; Exdensur access limited until its J-code, expected early July.
- HIV +10% with US +15%; Cabenuva +31%, Apretude +44%; three-times-yearly Apretude for PrEP targeted for H1 2027 launch and three-times-yearly Cabenuva for 2028.
- Pipeline: bepirovirsen (hepatitis B) has a US PDUFA date of 26 October and Priority Review in China; mo-rez (B7-H4 ADC) moving into five pivotal trials; 10 phase III starts planned in 2026.
- Business development: RAPT (ozureprubart, food allergy) and 35Pharma (HS235, pulmonary hypertension) acquired; Rockville site and linerixibat divested.
- Miels describes a fortnightly portfolio review with the CEO and R&D/commercial heads, "a Darwinian process" to move resources to winning programmes and accelerate the late-stage pipeline.
- Net debt at 1.4x EBITDA; CFO targets more than £10bn cash generated from operations; operating profit growth weighted to H2.
Questions about GSK
What does GSK do?
GSK discovers, develops and sells specialty medicines, vaccines and general medicines, focusing on respiratory, immunology and inflammation, oncology, HIV and infectious diseases.
What is GSK's revenue?
2025 turnover was £32.7bn (+7% CER) with Core operating profit of £9.8bn. H1 2026 sales were £16,038m (+5% CER).
How many employees does GSK have?
GSK has 66,800 people across 70 countries and 33 manufacturing sites, according to its 2025 Annual Report.
Who leads GSK?
Luke Miels succeeded Emma Walmsley as CEO at the end of 2025. Sir Jonathan Symonds is Chair and Julie Brown is CFO.
What is GSK's strategy?
GSK aims for sales above £40bn by 2031 by maximising launches, accelerating its late-stage pipeline, extending long-acting HIV medicines and adding assets through targeted business development.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)